Is obesity a causal factor of developing blood clots?

Av Søren Beck Jensen
Postdoktor

It is well known to most people that obesity is detrimental to health and that cardiovascular disease is a main concern. You may wonder if overweight in itself is the cause of these diseases so that weight loss would in fact prevent disease from developing. A study by Lindstrõm and colleagues published in the scientific journal Human Genetics shows that obesity is indeed a cause in the development of venous thrombosis, or a blood clot.

Continue reading

Be the first to like.

A new target for prevention of blood clots?

Av Robin Liang
Stipendiat ved TREC

Platelets play a role in the formation of blood clots, but the impact of their different receptors is still unclear. CLEC-2 is among the receptors found on platelets, and is important in maintaining the normal state of vessels in the presence of inflammation. As deep vein thrombosis (DVT) is a thromboinflammatory disorder involving a blood clot in the deep veins of the leg, CLEC-2 could be a receptor of interest in DVT research.

Continue reading

Be the first to like.

How immune responses and coagulation might influence each other

Av Gro Grimnes
Stipendiat ved TREC

When challenged with a bacterial infection, the immune system is activated, and through this, the body fights infection. This results in inflammation. Inflammation is closely linked to coagulation, and activated coagulation has been thought to contribute to microvascular and organ failure in severe infections.

Continue reading

Be the first to like.

Chances of getting another venous blood clot after an isolated blood clot in the vein

Av Nadia Arshad
Stipendiat ved TREC

Isolated superficial vein thrombosis (iSVT) is a blood clot in the vein that occurs frequently. Initially, it was thought to be a self-limiting condition. Later, researches have shown that the presence of such a clot could increase the chances of developing a clot in the deep vein (DVT) and in the lung, called a pulmonary embolism (PE). Clots in the deep veins and in the lungs are the two main complications of venous blood clots. What are the chances that a superficial blood clot reoccurs as a clot in the deep vein? This is not clear and few scientific studies have so far investigated this question. A recent study published in the Journal of Thrombosis and Hemostasis discussed the long-term chances of re-developing a blood clot in patients with a first-time superficial blood clot in the lower limbs and compared them with those having a blood clot above the knee (proximal DVT).

Continue reading

Be the first to like.

Kan blodprøve forutse tilbakevennende blodpropp hos kreftpasienter?

Av Line Holtet Evensen
Stipendiat ved TREC

Kreftsykdom er en kjent risikofaktor for venøs blodpropp, og opptil 25% av alle blodpropptilfeller forekommer blant kreftpasienter. Selv om alle pasienter med blodpropp har økt risiko for en tilbakevendende blodpropp i tiden etterpå og derfor behandles med blodfortynnende medisiner, er risikoen enda høyere hos kreftpasienter. Behandling av blodpropp er imidlertid ekstra utfordrende blant pasienter med kreft da disse også har en økt risiko for blødning som en komplikasjon av denne behandlingen. Det er derfor viktig å kunne identifisere kreftpasienter med spesielt høy risiko for tilbakevendende blodpropp for å kunne gi rett behandling.

Continue reading

Be the first to like.

The messenger that ages you, is the messenger you want to kill

Av Søren Beck Jensen
Postdoktor ved TREC

Endothelial cells line the interior surface of the blood vessels. Microparticles first described as cellular dust, are shed by endothelial cells to convey information via the blood stream. Recent research published in “Circulation” suggests that blood-borne microparticles from patients with acute coronary syndrome conveys a message that leads to premature aging of the endothelium, which may result in future cardiovascular disease. Continue reading

Be the first to like.

Kan nye medisiner være effektive i langtidsbehandling av blodpropp?

Av Benedikte Paulsen
Forskerlinjestudent ved TREC

Blant pasienter som har gjennomgått en venøs blodpropp er risikoen for å oppleve en ny blodpropp høy i tiden etter. Derfor behandles alle pasienter med blodfortynnende medisiner. Dagens retningslinjer sier at man skal behandles i tre til seks måneder etter å ha hatt en blodpropp, fordi man vil forebygge en ny propp, samt minimere risikoen for kompliserende blødning, som medisinen kan gi.

Continue reading

Be the first to like.

Kan fiskeolje forebygge blodpropp?

Av Trond Isaksen
Stipendiat ved TREC

Det er uenighet om omega-3 fettsyrer i fiskeolje kan forebygge blodpropp. Store befolkningsundersøkelser som Tromsøundersøkelsen hvor folk oppgir hvor mye fiskeolje de bruker kan si noe, men det er et problem at de som får blodpropp kan ha fellesnevnere utenom inntaket av omega-3. Det problemet kan unngås ved å studere en gruppe hvor en på forhånd vet at blodpropp vil oppstå hos en stor andel, og gi disse enten fiskeolje eller en placebo (juksemedisin). En gruppe australske forskere publiserte nylig en studie som ligner på et slikt optimalt eksperiment.

Continue reading

Be the first to like.

New medication with significantly lower bleeding rate

Av Timofey Sovershaev
Postdoktor ved TREC

Direct oral anticoagulants (DOACs) are a new class of drugs that prevent excess blood clotting. They are widely used due to a number of advantages over the previous generation of drugs (Vitamin K antagonists – Warfarin / Marevan), namely – more controlled effects, no need to do regular blood test to adjust the dose and fewer complications. This study talks about the comparative safety of three of those drugs.

Continue reading

1 person likes this post.